Cargando…
Efficacy and Toxicity Profile of Carfilzomib-Based Regimens for Treatment of Newly Diagnosed Multiple Myeloma: A Systematic Review
Carfilzomib (CFZ) is a proteasome inhibitor currently approved for the treatment of relapsed and refractory multiple myeloma (RRMM). Multiple trials are ongoing to evaluate its efficacy and safety in newly diagnosed multiple myeloma (NDMM). The use of CFZ-based two- or three-drug combination regimen...
Autores principales: | Imtiaz, Hassaan, Khan, Maimoona, Ehsan, Hamid, Wahab, Ahsan, Rafae, Abdul, Khan, Ali Y, Jamil, Abdur, Sana, Muhammad Khawar, Jamal, Abdullah, Ali, Taimoor Jaffar, Ansar, Iqraa, Khan, Muzammil M, Khouri, Jack, Anwer, Faiz |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8493667/ https://www.ncbi.nlm.nih.gov/pubmed/34629878 http://dx.doi.org/10.2147/OTT.S317570 |
Ejemplares similares
-
Relapsed breast cancer complicated by isolated brain metastasis
por: Ehsan, Hamid, et al.
Publicado: (2020) -
Role of Venetoclax in the Treatment of Relapsed and Refractory Multiple Myeloma
por: Ehsan, Hamid, et al.
Publicado: (2021) -
A Systematic Review of Transfusion-Transmissible Infections Among Blood Donors and Associated Safety Challenges in Pakistan
por: Ehsan, Hamid, et al.
Publicado: (2020) -
The Potential Vaccine Component for COVID-19: A Comprehensive Review of Global Vaccine Development Efforts
por: Khan, Israr, et al.
Publicado: (2020) -
Ocular Toxicity of Belantamab Mafodotin, an Oncological Perspective of Management in Relapsed and Refractory Multiple Myeloma
por: Wahab, Ahsan, et al.
Publicado: (2021)